These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

95 related articles for article (PubMed ID: 9293321)

  • 1. Paradoxical high-density lipoprotein reduction induced by fibrate therapy.
    Oleesky DA; Mir MA
    Ann Clin Biochem; 1997 Sep; 34 ( Pt 5)():573-4. PubMed ID: 9293321
    [No Abstract]   [Full Text] [Related]  

  • 2. Abnormal lipid profiles on fibrate derivatives.
    McLeod AJ; Warren RJ; Armitage M
    Lancet; 1996 Jan; 347(8996):261. PubMed ID: 8551900
    [No Abstract]   [Full Text] [Related]  

  • 3. [Overviews of fibrate].
    Tada N
    Nihon Rinsho; 2001 Mar; 59 Suppl 3():609-17. PubMed ID: 11347141
    [No Abstract]   [Full Text] [Related]  

  • 4. Marked removal of bezafibrate-induced high-density lipoprotein-cholesterol by low-density lipoprotein apheresis.
    Kawano M; Kuroda Y; Terao M; Yaginuma T; Kawakami M; Kanazawa Y
    Clin Chim Acta; 2002 Apr; 318(1-2):91-5. PubMed ID: 11880117
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Normocholesterolaemic dysslipidaemia: is there a role for fibrates?
    Hamilton-Craig I
    Med J Aust; 2001 Jun; 174(11):610; author reply 611. PubMed ID: 11453341
    [No Abstract]   [Full Text] [Related]  

  • 6. New developments in the treatment of low high-density lipoprotein cholesterol.
    Miller M
    Curr Atheroscler Rep; 1999 Jul; 1(1):24-30. PubMed ID: 11122688
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [BECAIT [Bezafibrate Coronary Atherosclerosis Intervention Trial]].
    Yoshino G; Hirano T; Kazumi T
    Nihon Rinsho; 2001 Mar; 59 Suppl 3():433-5. PubMed ID: 11347109
    [No Abstract]   [Full Text] [Related]  

  • 8. Lipid profiles on fibric-acid derivatives.
    Capps NE
    Lancet; 1994 Sep; 344(8923):684-5. PubMed ID: 7915370
    [No Abstract]   [Full Text] [Related]  

  • 9. A paradoxical severe decrease in serum HDL-cholesterol after treatment with a fibrate.
    Crook MA; Lynas J; Wray R
    J Clin Pathol; 2000 Oct; 53(10):796-7. PubMed ID: 11064678
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Severe decrease in serum HDL-cholesterol during combination therapy of bezafibrate and pioglitazone.
    Senba H; Kawano M; Kawakami M
    J Atheroscler Thromb; 2006 Oct; 13(5):263-4. PubMed ID: 17146155
    [No Abstract]   [Full Text] [Related]  

  • 11. Effect of baseline levels on response of high-density lipoprotein cholesterol to hypolipidemic treatment.
    Kolovou GD; Daskalova DC; Petropoulos II; Anagnostopoulou KK; Bilianou HI; Pilatis ND; Pavlidis AN; Cokkinos DV
    Am J Cardiol; 2003 Dec; 92(11):1339-42. PubMed ID: 14636917
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The hypolipidemic activity of novel benzofuran-2-carboxamide derivatives in Triton WR-1339-induced hyperlipidemic rats: a comparison with bezafibrate.
    Shattat G; Al-Qirim T; Sweidan K; Shahwan M; El-Huneidi W; Al-Hiari Y
    J Enzyme Inhib Med Chem; 2010 Dec; 25(6):751-5. PubMed ID: 20590406
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Paradoxical severe decrease in serum HDL-cholesterol after treatment with a fibrate: reply by the authors.
    Crook M; Lynas J; Wray R
    J Clin Pathol; 2002 Dec; 55(12):976. PubMed ID: 12461074
    [No Abstract]   [Full Text] [Related]  

  • 14. Bezafibrate reduces blood glucose in type 2 diabetes mellitus.
    Ogawa S; Takeuchi K; Sugimura K; Fukuda M; Lee R; Ito S; Sato T
    Metabolism; 2000 Mar; 49(3):331-4. PubMed ID: 10726910
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lovastatin versus bezafibrate for hyperlipemia treatment after heart transplantation.
    Hidalgo L; Zambrana JL; Blanco-Molina A; López-Granados A; Concha M; Casares J; Jiménez-Pérez J; López-Miranda J; Pérez-Jiménez F
    J Heart Lung Transplant; 1995; 14(3):461-7. PubMed ID: 7654731
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Simvastatin and bezafibrate increase cholesterol efflux in men with type 2 diabetes.
    Triolo M; Annema W; de Boer JF; Tietge UJ; Dullaart RP
    Eur J Clin Invest; 2014; 44(3):240-8. PubMed ID: 24325778
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Lipoproteins HDL and coronary artery disease: a molecular mechanism of fibrate].
    Kaletha K; Chodorowski Z; Anand IS; Rybakowska I; Nagel-Starczynowska G
    Przegl Lek; 2003; 60(4):223-5. PubMed ID: 14569888
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Increase in circulating levels of adiponectin after treatment with statin and fibrate in patients with coronary artery disease and hyperlipidemia.
    Nakamura T; Kodama Y; Takano H; Umetani K; Fujioka D; Saito Y; Kawabata K; Obata JE; Kitta Y; Kobayashi T; Mende A; Kugiyama K
    Atherosclerosis; 2007 Aug; 193(2):449-51. PubMed ID: 16997309
    [No Abstract]   [Full Text] [Related]  

  • 19. Pathophysiology and management of low high-density lipoprotein cholesterol.
    Rader DJ
    Am J Cardiol; 1999 May; 83(9B):22F-24F. PubMed ID: 10357571
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of endothelial function in patients with metabolic syndrome on bezafibrate or atorvastatin therapy.
    Hanefeld C; Bulut-Streich N; Bulut D; Graf C; Mügge A; Spiecker M
    Cardiovasc Drugs Ther; 2005 Mar; 19(2):153-5. PubMed ID: 16025235
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.